未名醫藥(002581.SZ)及相關當事人受到深交所公開譴責
格隆匯6月5日丨未名醫藥(002581.SZ)公佈，公司於2020年6月4日收到深圳證券交易所送達的《關於對山東未名生物醫藥股份有限公司及相關當事人給予公開譴責處分的決定》。
經查明，未名醫藥及相關當事人存在以下違規行為：控股股東非經營性佔用上市公司資金、關聯交易未及時履行審議程序和信息披露義務、信息披露不準確；
鑑於上述違規事實及情節，依據本所《股票上市規則(2018年11月修訂)》第17.2條、第17.3條、第17.4條和本所《深圳證券交易所中小企業板上市公司公開譴責標準》第五條、第六條的規定，經本所紀律處分委員會審議通過，本所作出如下處分決定：
一、對山東未名生物醫藥股份有限公司給予公開譴責的處分。
二、對山東未名生物醫藥股份有限公司控股股東北京北大未名生物工程集團有限公司、山東未名生物醫藥股份有限公司實際控制人兼董事長潘愛華給予公開譴責的處分。
三、對山東未名生物醫藥股份有限公司總經理丁學國、財務總監賴聞博、時任財務總監方言、董事會祕書王立君給予公開譴責的處分。
山東未名生物醫藥股份有限公司、北京北大未名生物工程集團有限公司、潘愛華、丁學國、賴聞博、方言、王立君如對本所作出的紀律處分決定不服的，可以在收到本紀律處分決定書之日起的十五個交易日內向本所申請複核。複核申請應當統一由未名醫藥通過本所上市公司業務專區提交，或者通過郵寄或者現場遞交方式提交給本所指定聯繫人。
對於山東未名生物醫藥股份有限公司及相關當事人的上述違規行為及本所給予的處分，本所將記入上市公司誠信檔案，並向社會公開。
公司及相關當事人特就此事向全體股東及廣大投資者致以誠摯的歉意！公司全體董事、監事和高級管理人員將以此為戒，嚴格遵守《公司法》、《證券法》等有關法律法規及《深圳證券交易所中小板股票上市規則》的有關規定，本着對公司、股東特別是中小投資者負責的態度，切實履行忠實義務及勤勉義務，確保公司依法依規運作，提升信息披露水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
